Hole N, Stern PL. Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer. 1990;45:179–84. https://doi.org/10.1002/ijc.2910450132.

Article  CAS  PubMed  Google Scholar 

Starzynska T, Rahi V, Stern PL. The expression of 5t4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66:867–9. https://doi.org/10.1038/bjc.1992.375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mieke W, Mulder C, Stern PL, Stukart MJ, De Windt E, Butzelaar RMJM, et al. Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res. 1997;3:1923–30. https://pubmed.ncbi.nlm.nih.gov/9815581/.

Google Scholar 

Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, Marinov G, et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS ONE. 2010;5. https://doi.org/10.1371/journal.pone.0009982.

Stern PL, Harrop R. 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother Springer Sci Bus Media Deutschland GmbH. 2017;415–26. https://doi.org/10.1007/s00262-016-1917-3.

Groothuis P, Jacobs D, Berentsen K, van der Vleuten M, Coumans R, Elgersma R, et al. Abstract 925: introduction to the preclinical profile of SYD1875, a novel site-specifically conjugated duocarmycin-based 5T4-targeting antibody-drug conjugate. Cancer Res. 2021;81:925–925. https://doi.org/10.1158/1538-7445.AM2021-925.

Article  Google Scholar 

Smith RA, Zammit DJ, Damle NK, Usansky H, Reddy SP, Lin J-H, et al. ASN004, a 5T4-targeting scFv-Fc antibody–drug Conjugate with High Drug-to-antibody ratio, induces complete and durable tumor regressions in preclinical models. Mol Cancer Ther. 2021;20:1327–37. https://doi.org/10.1158/1535-7163.mct-20-0565.

Article  CAS  PubMed  Google Scholar 

Zweit J, Shaw D, Stern P, Hastings D, Gillies J, Julyan P, et al. Iodine-124 positron emission tomography imaging of tumor targeted superantigen therapy in renal cell carcinoma patients. J Nucl Med. 2006;47:458P. http://jnm.snmjournals.org/content/47/suppl_1/458P.3.abstract.

Google Scholar 

Li Q, White JB, Peterson NC, Rickert KW, Lloyd CO, Allen KL, et al. Tumor uptake of pegylated diabodies: balancing systemic clearance and vascular transport. J Control Release. 2018;279:126–35. https://doi.org/10.1016/j.jconrel.2018.04.013.

Article  CAS  PubMed  Google Scholar 

Yang E, Liu Q, Huang G, Liu J, Wei W. Engineering nanobodies for next-generation molecular imaging. Drug Discov Today. 2022;27:1622–38. https://doi.org/10.1016/j.drudis.2022.03.013.

Article  CAS  PubMed  Google Scholar 

Liberini V, Laudicella R, Capozza M, Huellner MW, Burger IA, Baldari S, et al. The future of Cancer diagnosis, treatment and surveillance: a systemic review on Immunotherapy and Immuno-PET Radiotracers. Molecules. 2021;26:2201. https://doi.org/10.3390/molecules26082201.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fayn S, King AP, Gutsche NT, Duan Z, Buffington J, Olkowski CP, et al. Site-specifically conjugated single-domain antibody successfully identifies glypican-3-Expressing Liver Cancer by Immuno-PET. J Nucl Med. 2023;64:1017–23. https://doi.org/10.2967/jnumed.122.265171.

Article  CAS  PubMed  PubMed Central  Google Scholar 

You Z, Zhou W, Weng J, Feng H, Liang P, Li Y, et al. Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis. Cancer Cell Int BioMed Cent Ltd. 2021. https://doi.org/10.1186/s12935-021-02187-1.

Article  Google Scholar 

Li L, Lin X, Wang L, Ma X, Zeng Z, Liu F, et al. Immuno-PET of colorectal cancer with a CEA-targeted [68Ga]Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023;50:3735–49. https://doi.org/10.1007/s00259-023-06313-1.

Article  CAS  PubMed  Google Scholar 

Xavier C, Vaneycken I, D’Huyvetter M, Heemskerk J, Keyaerts M, Vincke C, et al. Synthesis, preclinical validation, dosimetry, and toxicity of a-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54:776–84. https://doi.org/10.2967/jnumed.112.111021.

Article  CAS  PubMed  Google Scholar 

Xu C, Zhu M, Wang Q, Cui J, Huang Y, Huang X, et al. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer. J Nanobiotechnol. 2023;21. https://doi.org/10.1186/s12951-023-02183-9.

Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435–42. https://doi.org/10.1089/cbr.2008.0464.

Article  PubMed  Google Scholar 

Feng Y, Sarrett SM, Meshaw RL, Vaidyanathan G, Cornejo MA, Zeglis BM, et al. Site-specific Radiohalogenation of a HER2-Targeted single-domain antibody fragment using a Novel Residualizing Prosthetic Agent. J Med Chem. 2022;65:15358–73. https://doi.org/10.1021/acs.jmedchem.2c01331.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cleeren F, Lecina J, Ahamed M, Raes G, Devoogdt N, Caveliers V, et al. Al18F-labeling of heat-sensitive biomolecules for positron emission tomography imaging. Theranostics. 2017;7:2924–39. https://doi.org/10.71502/Fthno.20094.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cleeren F, Lecina J, Bridoux J, Devoogdt N, Tshibangu T, Xavier C, Bormans G. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. Nat Protoc. 2018;13:2330–47. https://doi.org/10.1038/s41596-018-0040-7.

Article  CAS  PubMed  Google Scholar 

Yao Y, Hou X, Liu S, Liu T, Ren Y, Ma X, et al. Construction and preclinical evaluation of a 124/125I-Labeled specific antibody targeting PD-L2 in Lung Cancer. Mol Pharm. 2023;20:1365–74. https://doi.org/10.1021/acs.molpharmaceut.2c00958.

Article  CAS  PubMed  Google Scholar 

Jiang D, Lu X, Li Z, Rydberg N, Zuo C, Peng F, et al. Increased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) expression in adolescent brain development: a longitudinal micro-PET/CT study in rodent. Front Neurosci. 2019;12. https://doi.org/10.3389/fnins.2018.01052.

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.3389/fnins.2018.01052.

Article  CAS  PubMed  Google Scholar 

Xie T, Zaidi H. Evaluation of radiation dose to anthropomorphic paediatric models from positron-emitting labelled tracers. Phys Med Biol. 2014;59:1165–87. https://doi.org/10.1088/0031-9155/59/5/1165.

Article  CAS  PubMed  Google Scholar 

Xie T, Zanotti-Fregonara P, Edet-Sanson A, Zaidi H. Patient-specific computational model and dosimetry calculations for PET/CT of a patient pregnant with twins. J Nucl Med. 2018;59:1451–8. https://doi.org/10.2967/jnumed.117.205286.

Article  PubMed  Google Scholar 

Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund K, et al. ICRP publication 128: Radiation dose to patients from Radiopharmaceuticals: a compendium of current information related to frequently used substances. Ann ICRP. 2015;44:7–321. https://doi.org/10.1177/0146645320936035.

Article  CAS  PubMed  Google Scholar 

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase i study of 68Ga-HER2-Nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57:27–33. https://doi.org/10.2967/jnumed.115.162024.

Article  CAS  PubMed  Google Scholar 

Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54:855–60. https://doi.org/10.2967/jnumed.112.114165.

Article  CAS  PubMed  Google Scholar 

Sharma A, Blériot C, Currenti J, Ginhoux F. Oncofetal reprogramming in tumour development and progression. Nat Rev Cancer. 2022;22:593–602. https://doi.org/10.1038/s41568-022-00497-8.

Article  CAS  PubMed  Google Scholar 

Marchand A, Fenoglio CM, Pascal R, Richart RM, Bennett S. Carcinoembryonic antigen in human ovarian neoplasms. Cancer Res. 1975;35:3807–10. https://aacrjournals.org/cancerres/article/35/12/3807/480498/Carcinoembryonic-Antigen-in-Human-Ovarian.

CAS  PubMed  Google Scholar 

Laurence DTR, Stevens U, Bettelheim R, Darcy D, Leese C, Turberville C, et al. Role of plasma Carcinoembryonic Antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma. Br Med J. 1972;3:605–9. https://doi.org/10.1136/bmj.3.5827.605.

Article  CAS  PubMed